title: Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer.
abstract: MicroRNA-203 (miR-203), possessing tumor suppressive or promotive activities, has been found to be downregulated or upregulated in different cancer types. The purpose of this study was to investigate whether the increased expression of miR-203 can be used as a noninvasive diagnostic and prognostic biomarker in epithelial ovarian cancer (EOC). Real-time quantitative PCR was performed to detect the expression levels of miR-203 in EOC tissues. The expression levels of miR-203 were significantly higher in EOC tissues compared to adjacent non-cancerous tissues (p < 0.001). High expression of miR-203 was observed in 65.38 % (102/156) of EOC. In addition, high miR-203 expression was found to be closely correlated with advanced FIGO stage (p < 0.001), higher histological grade (p = 0.02), lymph node involvement (p < 0.001), and positive recurrence (p < 0.001). Moreover, high miR-203 expression was correlated with shorter overall survival (p < 0.001) and shorter progression-free survival (p < 0.001) of EOC patients. Furthermore, multivariate analysis showed that the status of miR-203 expression was an independent predictor for both overall survival and progression-free survival in EOC. These findings provide the convincing evidence for the first time that the upregulation of miR-203 may serve as a novel molecular marker to predict the aggressive tumor progression and unfavorable prognosis of EOC patients.
authors.affiliation: Maternal and Child Health Hospital of Hainan Province, No. 15, Long Kun Nan Road, Haikou, 570206, Hainan, China.
authors.forename: Shaosheng
authors.initials: S
authors.lastname: Wang
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Zhao
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.forename: Yingmei
authors.initials: Y
authors.lastname: Wen
authors.forename: Linjing
authors.initials: L
authors.lastname: Zhang
authors.forename: Dezhu
authors.initials: D
authors.lastname: Wang
authors.forename: Huili
authors.initials: H
authors.lastname: Chen
authors.forename: Qiuxia
authors.initials: Q
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Xiang
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics; D000077216:Carcinoma, Ovarian Epithelial; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D011379:Prognosis; D015854:Up-Regulation / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; C546703:MIRN203 microRNA, human; D035683:MicroRNAs
references.citation: Physiol Genomics. 2011 May 1;43(10):640-54
references.pmid: 21406606
references.citation: Oncol Rep. 2012 Apr;27(4):1238-44
references.pmid: 22246341
references.citation: BMC Cancer. 2011 Feb 07;11:57
references.pmid: 21299870
references.citation: J Physiol Biochem. 2011 Mar;67(1):129-39
references.pmid: 20981514
references.citation: Nat Rev Cancer. 2006 Apr;6(4):259-69
references.pmid: 16557279
references.citation: Biochim Biophys Acta. 2010 Apr;1805(2):209-17
references.pmid: 19931352
references.citation: Asian Pac J Cancer Prev. 2013;14(4):2289-93
references.pmid: 23725129
references.citation: BioDrugs. 2007;21(2):97-104
references.pmid: 17402793
references.citation: N Engl J Med. 2004 Dec 9;351(24):2519-29
references.pmid: 15590954
references.citation: Bioorg Khim. 2010 Nov-Dec;36(6):747-52
references.pmid: 21317939
references.citation: FEBS J. 2011 Mar;278(5):786-92
references.pmid: 21205209
references.citation: Cell. 2004 Jan 23;116(2):281-97
references.pmid: 14744438
references.citation: Nat Rev Cancer. 2006 Nov;6(11):857-66
references.pmid: 17060945
references.citation: J Int Med Res. 2013 Feb;41(1):64-71
references.pmid: 23569131
references.citation: CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
references.pmid: 11577478
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7850-60
references.pmid: 19047114
references.citation: Cancer Res. 2007 Sep 15;67(18):8699-707
references.pmid: 17875710
references.citation: Cell. 2001 Dec 28;107(7):823-6
references.pmid: 11779458
references.citation: Cell Cycle. 2011 Apr 1;10(7):1121-31
references.pmid: 21368580
references.citation: Science. 2008 Mar 28;319(5871):1785-6
references.pmid: 18369135
references.citation: Genes Cancer. 2011 Aug;2(8):782-91
references.pmid: 22393463
references.citation: Exp Ther Med. 2013 May;5(5):1315-1321
references.pmid: 23737871
references.citation: Ann Surg Oncol. 2010 Dec;17(12):3120-8
references.pmid: 20652642
references.citation: J Carcinog. 2012;11:18
references.pmid: 23230394
references.citation: Int J Gynecol Cancer. 2013 May;23(4):673-9
references.pmid: 23542579